Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Current Assets (2023 - 2025)

Historic Current Assets for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $2.9 billion.

  • Genmab A's Current Assets fell 2602.56% to $2.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 billion, marking a year-over-year decrease of 2602.56%. This contributed to the annual value of $2.9 billion for FY2025, which is 2602.56% down from last year.
  • Latest data reveals that Genmab A reported Current Assets of $2.9 billion as of Q4 2025, which was down 2602.56% from $4.5 billion recorded in Q3 2025.
  • In the past 5 years, Genmab A's Current Assets ranged from a high of $4.9 billion in Q4 2023 and a low of -$335.0 million during Q1 2024
  • Over the past 3 years, Genmab A's median Current Assets value was $3.9 billion (recorded in 2024), while the average stood at $3.4 billion.
  • Data for Genmab A's Current Assets shows a peak YoY increase of 130507.46% (in 2025) and a maximum YoY decrease of 2602.56% (in 2025) over the last 5 years.
  • Genmab A's Current Assets (Quarter) stood at $4.9 billion in 2023, then dropped by 20.6% to $3.9 billion in 2024, then decreased by 26.03% to $2.9 billion in 2025.
  • Its Current Assets was $2.9 billion in Q4 2025, compared to $4.5 billion in Q3 2025 and $3.9 billion in Q2 2025.